Pro-Dex (PDEX) Expected to Announce Earnings on Thursday

Pro-Dex (NASDAQ:PDEX) is expected to post its Q2 2026 results before the market opens on Thursday, January 29th. Analysts expect Pro-Dex to post earnings of $0.59 per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, February 2, 2026 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The firm had revenue of $18.53 million for the quarter, compared to analyst estimates of $15.30 million. Pro-Dex had a net margin of 15.94% and a return on equity of 23.64%. On average, analysts expect Pro-Dex to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pro-Dex Trading Down 2.1%

NASDAQ PDEX opened at $40.85 on Thursday. Pro-Dex has a 1 year low of $23.47 and a 1 year high of $70.26. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.73 and a quick ratio of 2.14. The company has a market capitalization of $133.17 million, a PE ratio of 12.19 and a beta of -0.05. The company has a fifty day moving average of $39.00 and a 200 day moving average of $38.92.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Pro-Dex in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Hedge Funds Weigh In On Pro-Dex

Large investors have recently bought and sold shares of the business. Osaic Holdings Inc. boosted its position in Pro-Dex by 23.6% during the second quarter. Osaic Holdings Inc. now owns 7,120 shares of the medical instruments supplier’s stock worth $311,000 after purchasing an additional 1,360 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Pro-Dex during the 1st quarter worth approximately $321,000. JPMorgan Chase & Co. lifted its position in shares of Pro-Dex by 67.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier’s stock valued at $1,566,000 after buying an additional 14,479 shares in the last quarter. Punch & Associates Investment Management Inc. lifted its position in shares of Pro-Dex by 42.1% during the 3rd quarter. Punch & Associates Investment Management Inc. now owns 48,608 shares of the medical instruments supplier’s stock valued at $1,645,000 after buying an additional 14,408 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in Pro-Dex in the 2nd quarter valued at $105,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.